Kousai Biotech Secures RMB Hundred-Million Series A Financing to Advance DC Vaccine Development, MedBio Capital Acts as Exclusive Financial Advisor

VCBeat learned第一时间 that Hengsai Biotech, following its multi-million financing last year, has successfully completed another billion-level A-round financing this year. This round of financing was led byFuho CapitalLeading investment,Triwise Capital, Gongqingcheng Kaiqi Kangying No.1 Venture Capital Partnership (Limited Partnership)Co-investment,MedBio CapitalAct as the exclusive financial advisor.

Hengsai Biotech, founded in 2018, is a science and technology innovation enterprise dedicated to the research and industrialization of dendritic cell vaccines (DC vaccines) and a national high-tech enterprise. The company has successfully built the Eco-DCVax platform, aiming to break through industrial technical barriers and develop high-quality DC vaccine products with independent intellectual property rights that are global First-in-Class, safe, efficient, and convenient for administration. The developed product—therapeutic dendritic cell vaccine—provides new treatment pathways and strategies for diseases that urgently need effective treatments clinically, such as recurrent and refractory tumors, chronic viral infections, and autoimmune diseases.

Hengsai Biotech's R&D center and pilot plant located in Lanwan, Lingang, Shanghai, were officially put into use in 2021. A large-scale R&D/production base is currently under construction. The company has now established stable cooperative relationships with multiple domestic and international scientific research institutions and Class III Grade A hospitals. It is in the process of dual filing in China and the United States, conducting clinical research and technical cooperation to comprehensively verify the clinical safety and efficacy of DC vaccines.

Currently, there are no DC vaccine products approved for marketing in China. Hengsai Biotech has established a comprehensive R&D platform and technical system for DC vaccines, including internationally leading technologies such as DC cell separation and induction, tumor antigen selection and loading platforms, clinical trial-grade DC cell production centers, and quality control and management systems. Based on overseas cutting-edge DC vaccine R&D experience, the company’s technology has been further improved to establish standardized, regulated, and industrialization-friendly methods for DC vaccine production. The overall technical level is internationally leading, with multiple patented inventions, filling the gap in this field domestically.

Dr. Hui-Ning Liu, Founder and CEO of Hengsai BiotechHengsai Bio has a relatively mature DC vaccine preparation process and a scientifically compliant quality control system. We are very grateful for the recognition and trust from this round of investors, including Fuho Capital, Triwise Capital, and Gongqingcheng Kaiqi Kangying No.1 Venture Capital Partnership (Limited Partnership), as well as the support from MedBio Capital. This round of financing will help us advance the expansion of our product pipeline and clinical applications. The Hengsai team will continue to be guided by clinical needs and driven by technological innovation to develop safer, more effective, and accessible DC vaccines.

Fuho Capital Investment TeamFuho Capital Deepens Strategic Cooperation with Shanghai Institute of Materia Medica, Chinese Academy of Sciences, and Zhongshan Municipal Government, Committed to Promoting the Development of High-quality Innovative Pharmaceutical Enterprises in Cuiheng New District, Zhongshan. Hengsai Biotech, a Leading Domestic DC Cell Therapy Enterprise, is a Representative of Our Long-term Collaborative and Service-oriented High-quality Enterprises. We Will Continue to Support the Rapid Growth of Hengsai Biotech, Aiming to Become a Global Leader in DC Cell Therapy.

Triwise Capital Investment TeamHengsai Biotech's new generation of DC vaccine technology has many advantages, which gives it broad application prospects. The company's core founding team has years of experience in cell therapy, and has established a relatively mature DC vaccine preparation process, as well as a scientifically compliant quality control system. These factors will contribute to the company’s long-term stable development. We look forward to Hengsai Biotech's DC vaccine bringing positive impact and substantial help to patients as soon as possible.

Chen Bo, Managing Partner of Gongqingcheng Kaiqi Kangying No.1 Venture Capital Partnership (Limited Partnership)Hengsai Biotech has developed an internationally leading DC vaccine culture technology, which optimally demonstrates antigen universality and effectiveness, paving a new way for highly effective and easily industrialized tumor vaccines. We look forward to seeing Hengsai continuously tackle various virus-induced tumor diseases, bringing benefits to patients suffering from such "incurable" conditions.

Mr. Ding Huanxing, Partner of MedBio CapitalDC vaccines have the advantages of low cost, good efficacy, low side effects, and convenient clinical use. Hengsai Biotech has made rapid and significant progress in R&D after the previous round of financing. We believe that after this round of financing, Hengsai Biotech will lead the development of the DC vaccine industry.

Fuho Capital is a VC investment institution focusing on the transformation of scientific and technological achievements and early-stage investments in technology companies. Its invested projects in the healthcare field include several high-quality enterprises such as New Horizon Health (06606.HK), Airdoc Technology (02251.HK), Kexin Kaidi, Zhiben Pharmaceuticals, Huazi Biotech, Baiji Hongye, Uli Pharmaceuticals, Loci Biotech, and Ruishun Biotech.

Shenzhen Qianhai Triwise International Capital Management Co., Ltd. has gathered seasoned professionals from Shenzhen Capital Group, Roche, GSK, BMS, Abbvie, AstraZeneca, and BGI Group. The company has offices in Shenzhen, Shanghai, Hangzhou, Changzhou, Dongguan, and Zhongshan, and has initiated the establishment of nearly forty RMB and USD funds. In January 2023, it was awarded "TOP 30 China Growth-Oriented VC Investment Institutions of the Year" on the 2022 China Venture Capital Industry Annual List.

Gongqingcheng Kaiqi Kangying No.1 Venture Capital Partnership (Limited Partnership) is an industrial investment enterprise that specializes in investing in cutting-edge biopharmaceutical companies. It is composed of seasoned healthcare investors and has previously invested in several highly promising early-stage enterprises.

MedBio Capital is a boutique investment bank focused on the life sciences and healthcare sectors, dedicated to becoming the capital and strategic partner for top scientists and entrepreneurs. The core team has deep roots in the healthcare industry, covering key nodes in research and development, clinical trials, and market dynamics, with a composite background in investment, investment banking, and consulting. Team members have collectively completed financing exceeding tens of billions and have served more than a dozen top-tier publicly listed healthcare companies.